Search research articles
Contact Us
Filters
Showing results (171-180 of 183) with videos related to
Page
of 19
Sort By:
Medicine
|
January 14, 2022
Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis
Kuang-Hui Yu, Hsin-Hua Chen, Tien-Tsai Cheng, et al.
Lancet (London, England)
|
February 8, 2011
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, et al.
EMBO Molecular Medicine
|
October 31, 2025
ZNF334 truncation mutation drives cold-induced autoinflammation
Joung-Liang Lan, Shih-Hsin Chang, Yi-Hua Lai, et al.
Free Radical Biology & Medicine
|
January 18, 2021
Redox sensor NPGPx restrains ZAP70 activity and modulates T cell homeostasis
Fang-Yi Su, Shih-Chia Huang, Pei-Chi Wei, et al.
Clinical Immunology (Orlando, Fla.)
|
August 23, 2025
"Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis"
Yung-Ju Yeh, Hsin-Yi Peng, Ting-Yin Xue, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2005
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Shuen-Iu Hung, Wen-Hung Chung, Lieh-Bang Liou, et al.
International Journal of Rheumatic Diseases
|
April 9, 2010
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
, Annie Wai-Chee Kung, Ichramsjah A Rachman, et al.
Annals of the Rheumatic Diseases
|
December 6, 2025
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
Nancy Agmon-Levin, Stanislav Ignatenko, Alexander Gordienko, et al.
Innovation (Cambridge (Mass.))
|
December 8, 2021
Artificial intelligence: A powerful paradigm for scientific research
Yongjun Xu, Xin Liu, Xin Cao, et al.
Leukemia
|
April 7, 2019
Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma
Xiao-Peng Tian, Wei-Juan Huang, Hui-Qiang Huang, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 183) with videos related to
Sort By:
Page
of 19
Medicine
|
January 14, 2022
Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis
Kuang-Hui Yu, Hsin-Hua Chen, Tien-Tsai Cheng, et al.
Lancet (London, England)
|
February 8, 2011
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, et al.
EMBO Molecular Medicine
|
October 31, 2025
ZNF334 truncation mutation drives cold-induced autoinflammation
Joung-Liang Lan, Shih-Hsin Chang, Yi-Hua Lai, et al.
Free Radical Biology & Medicine
|
January 18, 2021
Redox sensor NPGPx restrains ZAP70 activity and modulates T cell homeostasis
Fang-Yi Su, Shih-Chia Huang, Pei-Chi Wei, et al.
Clinical Immunology (Orlando, Fla.)
|
August 23, 2025
"Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis"
Yung-Ju Yeh, Hsin-Yi Peng, Ting-Yin Xue, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2005
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Shuen-Iu Hung, Wen-Hung Chung, Lieh-Bang Liou, et al.
International Journal of Rheumatic Diseases
|
April 9, 2010
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
, Annie Wai-Chee Kung, Ichramsjah A Rachman, et al.
Annals of the Rheumatic Diseases
|
December 6, 2025
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
Nancy Agmon-Levin, Stanislav Ignatenko, Alexander Gordienko, et al.
Innovation (Cambridge (Mass.))
|
December 8, 2021
Artificial intelligence: A powerful paradigm for scientific research
Yongjun Xu, Xin Liu, Xin Cao, et al.
Leukemia
|
April 7, 2019
Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma
Xiao-Peng Tian, Wei-Juan Huang, Hui-Qiang Huang, et al.
Page
of 19